Protocol approach 1: immune rebalancing (thymosin alpha-1 plus KPV) Goal: Restore regulatory immune function while reducing inflammatory signaling Components: Thymosin alpha-1: 1.6 mg subcutaneously twice per week (promotes Treg expansion, modulates dendritic cells) KPV: 200-500 mcg daily, orally or subcutaneously (inhibits NF-kB, reduces TNF-alpha and IL-6) Rationale: Thymosin alpha-1 works at the cellular level to rebuild the regulatory arm of the immune system, while KPV addresses the inflammatory signaling that drives acute symptoms
Alicante is a much smaller and friendlier airport or maybe my Spanish relations make it all easier there
All data presented is from clinical trials for educational reference
(PubMed) Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R
It is not a drug, food, or cosmetic , and must not be misused, misbranded, or represented as such
CDs containing porphyrin are minuscule in size, have good water solubility and are photostable [121]